EAU 2013 - Programme Book - YouMed

Sponsored Sessions
Sunday, 17 March
414 Programme Book
Sponsored Session
17.45 - 19.15 Burden of illness and optimal management of recurrent cystitis
Amber Hall 1-2 - Level S2
Symposium
Chair: K.G. Naber, Straubing (DE)
Antimicrobial susceptibility and resistance in urological infections worldwide: Surveillance and prevention
F.M.E. Wagenlehner, Giessen (DE)
Guidelines in urinary tract infections (UTI): The place of immunoactive-prophylaxis in recurrent UTI
management
K.G. Naber, Straubing (DE)
Burden of illness of recurrent UTI: Clinical benefit of oral immunostimulation and impact on patients’ quality
of life
B. Wullt, Lund (SE)
Responders profile and evidence in clinical practice
P. Tenke, Budapest (HU)
Aims and objectives
Progressive increase of antibiotic resistance is a major concern worldwide. Resistance surveillance programs
and infection control measures may be useful in delaying resistance, but rarely capable to reduce the incidence
of infections caused by multi-drug resistant (MDR) organisms. On the other hand, new antimicrobials will not
likely become available before the next decade. Specifically, with regard to recurrent urinary tract infection
(rUTI), the increasing resistance to several antibiotic classes support the need to use alternative preventative
approaches in order to spare the limited antibiotic armamentarium.
European Association of Urology (EAU) Guidelines recommend: i) counseling and behavioral modifications
to eliminate modifiable risk factors for rUTI and ii) non-antimicrobial prophylaxis before any antibiotic
prevention. Several non-antimicrobial measures that do not increase antibiotic resistance are currently
available with different grades of recommendation according to the scientific level of evidence.
The oral immunoactive prophylaxis with E.coli extracts (OM-89) deserves the highest grade of recommendation
in the EAU Guidelines compared to other alternative strategies because its efficacy is sufficiently well
documented in several randomized double blind placebo controlled studies and 2 meta-analysis.
The immunological properties and the clinical safety and efficacy of oral bacterial lysates (OM-89) will be
addressed in details in the symposium. Furthermore the detrimental impact of recurrent cystitis on patients’
quality of life will also be highlighted and the beneficial effects of the immunoactive therapy on life quality
indicators will be presented.
There is some evidence that specific populations, including patients at higher risk for recurrent cystitis, could
benefit more by immunoprophylaxis but further controlled studies are desirable. In the meantime, useful
evidence comes from daily clinical practice; some case studies will be shown and debated.
Sponsored by OM PHARMA SA